Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron PharmafiledCriticalRegeneron Pharma
Publication of ECSP088993ApublicationCriticalpatent/ECSP088993A/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
La invención se refiere a un composición farmacéutica que comprende un anticuerpo humano o fragmento de unión de antígeno de un anticuerpo humano que se une específicamente a hlL-6R y de un vehículo farmacéuticamente aceptable.The invention relates to a pharmaceutical composition comprising a human antibody or antigen binding fragment of a human antibody that specifically binds hlL-6R and a pharmaceutically acceptable carrier.
ECSP0889932006-06-022008-12-18
HIGH AFFINITY ANTIBODIES TOWARDS RECEPTOR OF HUMAN IL-6
ECSP088993A
(en)
Monoclonal antibodies that specifically bind to an amyloid-beta peptide, methods for producing them, pharmaceutical compositions comprising same and use thereof for the manufacture of medicaments
Bispecific antigen-binding protein, comprising a) 2 light chains and 2 heavy chains of an antibody that specifically binds to one antigen and 2 fab fragments, b) two additional fab fragments of an antibody that specifically bind to a second antigen ; Preparation method; pharmaceutical composition and use.
Human antibody that binds to the ligand for human ox40 (ox40l or gp34); Method of production; and pharmaceutical composition that includes it (div. sol. n ° 2389-05).
Isolated antibody or antigen binding fragment thereof that specifically binds to human cd48 and blocks the interaction between human cd48 and a cd48 receptor; pharmaceutical composition that includes it; And its use.
Antibody or functional fragment of the antibody, pharmaceutical composition, use of at least one of the antibodies or functional fragments of the antibodies, and hybridoma